Valneva/$VALN
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Valneva
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
- Ticker
- $VALN
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 620
- Headquarters
- Saint-Herblain, France
- Website
- valneva.com
Valneva Metrics
BasicAdvanced
$564M
-
-$0.98
1.37
-
Price and volume
Market cap
$564M
Beta
1.37
52-week high
$12.18
52-week low
$4.75
Average daily volume
22K
Financial strength
Current ratio
2.157
Quick ratio
1.334
Long term debt to equity
2.331
Total debt to equity
2.592
Interest coverage (TTM)
-2.83%
Profitability
EBITDA (TTM)
-109.372
Gross margin (TTM)
-41.73%
Net profit margin (TTM)
-110.29%
Operating margin (TTM)
-80.38%
Effective tax rate (TTM)
-0.05%
Revenue per employee (TTM)
$254,810
Management effectiveness
Return on assets (TTM)
-16.68%
Return on equity (TTM)
-117.85%
Valuation
Price to revenue (TTM)
6.673
Price to book
6.26
Price to tangible book (TTM)
8.43
Price to free cash flow (TTM)
-16.434
Free cash flow yield (TTM)
-6.08%
Free cash flow per share (TTM)
-0.36
Growth
Revenue change (TTM)
-27.19%
Earnings per share change (TTM)
107.91%
3-year revenue growth (CAGR)
-30.49%
10-year revenue growth (CAGR)
4.11%
3-year earnings per share growth (CAGR)
156.99%
10-year earnings per share growth (CAGR)
0.57%
What the Analysts think about Valneva
Analyst ratings (Buy, Hold, Sell) for Valneva stock.
Analyst projections of the future price of Valneva stock.
Bulls say / Bears say
The Lyme vaccine candidate produced more than 70% efficacy in Phase 3 and was well tolerated, giving Valneva a strong late-stage asset with Pfizer. (Valneva)
Valneva had €121.5 million in cash at June-end and has launched a restructuring programme to lower costs. This provides a financial buffer while it pursues the Lyme vaccine and reduces operating expenses. (Valneva)
First-half product sales fell to €64.0 million from €91.0 million a year earlier, leaving Valneva reliant on a narrower commercial portfolio as third-party distribution winds down. (Valneva)
The company’s first-half net loss widened to €63.3 million from €20.8 million, while cash at June-end was supported by a €37 million share offering. Continued losses could mean further financing and dilution. (Valneva)
Data summarised monthly by Lightyear AI. Last updated on 2 Nov 2026.
Valneva Financial Performance
Revenues and expenses
Valneva Earnings Performance
Company profitability
Upcoming events
No upcoming events
Valneva News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.